Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies
Authors' conclusion
Anti-Sp4 autoantibodies appear to identify a subgroup of anti-TIF1γ-positive DM patients with lower cancer risk.
Study context
- Population
- Johns Hopkins patients with myositis, rheumatological disease controls and healthy comparators; validation cohort of anti-TIF1γ-positive patients from the University of Pittsburgh371 myositis, 80 disease controls, 200 healthy
- Participants
- 26 vs 35
- Exposure
- Anti-TIF1γ-positive dermatomyositis (DM) patients with vs without anti-Sp4 autoantibodies
- TIF1γ-positive with anti-Sp4n = 26
- TIF1γ-positive without anti-Sp4n = 35reference
- Outcome
- Cancer in anti-TIF1γ-positive DM patients by anti-Sp4 status
Methodological detailsautoantibody discovery (Phage ImmunoPrecipitation Sequencing), ELISA screening, validation cohort
- Autoantibody discovery (Phage ImmunoPrecipitation Sequencing)
- ELISA screening
- Validation cohort
Main finding
As reported in the abstract
Cancer among TIF1γ-positive patients (Johns Hopkins cohort)
P = 0.04
Observational data: associations, not effects.
Further findings
| Outcome | TIF1γ-positive with anti-Sp4 | P value |
|---|---|---|
| Cancer among TIF1γ-positive patients (validation cohort)Anti-Sp4 positive vs Anti-Sp4 negative | 13.3% | P < 0.001 |
- Prevalence of anti-Sp4 autoantibodies — Anti-Sp4 in DM detected in those with anti-TIF1γ autoantibodies
- 96.3%
- Cancer among TIF1γ-positive patients (validation cohort): Anti-Sp4 negative 67.7%
- Cancer among TIF1γ-positive patients (validation cohort): validation cohort: 15 vs 31 patients
- Prevalence of anti-Sp4 autoantibodies: DM 10.5%
- Prevalence of anti-Sp4 autoantibodies: Rheumatoid arthritis (RA) 3.3%
Prevalence of anti-Sp4 autoantibodies
- Not present in other clinical groups
Original publication
Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies. Ann Rheum Dis. Published 25 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →